Moreover, the same inhibitor also demonstrated that inhibition of PRMT5 significantly reduced gemcitabine resistance in pancreatic cancer caused by UBR7 depletion (Table 4) (Bi et al., 2023). This evidence concerns the gene UBR7 and pancreatic neoplasm.